2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.
about
Phosphodiesterase 4-targeted treatments for autoimmune diseasesDecreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritisNon-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)TNF-alpha inhibitors for ankylosing spondylitisSulfasalazine for ankylosing spondylitisNon-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-AnalysisOld and new treatment targets in axial spondyloarthritisMaking the next steps in psoriatic arthritis management: current status and future directionsTreatment of juvenile idiopathic arthritis: a revolution in careNew targets in psoriatic arthritisShould axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study.[Evaluation of performance of BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) in a Brazilian cohort of 1,492 patients with spondyloarthritis: data from the Brazilian Registry of Spondyloarthritides (RBE)].Ankylosing spondylitis in iran; late diagnosis and its causes.Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers.Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effectDiscovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis.IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapyReferral patterns, diagnosis, and disease management of patients with axial spondyloarthritis: results of an international surveyDiscontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trialEvaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.Management of arthropathy in inflammatory bowel diseases.Adalimumab-induced lupus serositis.Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease SeverityBiologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany.Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.Juvenile spondyloarthritis treatment recommendationsEffectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort.Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012.Impact of Dose Tapering of Tumor Necrosis Factor Inhibitor on Radiographic Progression in Ankylosing Spondylitis.The effect of three years of TNFα blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study.Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab.Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspectiveComparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS studyIL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patientsHepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study.Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.
P2860
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
P2860
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
2010 Update of the internation ...... with axial spondyloarthritis.
@en
2010 Update of the internation ...... with axial spondyloarthritis.
@nl
type
label
2010 Update of the internation ...... with axial spondyloarthritis.
@en
2010 Update of the internation ...... with axial spondyloarthritis.
@nl
prefLabel
2010 Update of the internation ...... with axial spondyloarthritis.
@en
2010 Update of the internation ...... with axial spondyloarthritis.
@nl
P2093
P50
P921
P356
P1476
2010 Update of the internation ...... with axial spondyloarthritis.
@en
P2093
Assessment of SpondyloArthritis international Society
Joachim Sieper
Jürgen Braun
Martin Rudwaleit
Rubén Burgos-Vargas
P304
P356
10.1136/ARD.2011.151563
P407
P577
2011-06-01T00:00:00Z